Pictured, from left: Delaney; Dave Heimbrook, Ph.D., Laboratory Director, Frederick National Laboratory for Cancer Research, and President, Leidos Biomedical Research, Inc.; M.K. Holohan, NCI Legislative Office; Dr. Shyam Sharan, Deputy Director, Mouse Genetics Program; Craig Reynolds, Ph.D., Director of Scientific Operations, NCI at Frederick, and Associate Director, National Cancer Institute; Steve Davis, Chief, Management Operations Support Branch, NCI at Frederick; and Blair Feldman, NCI Legislative Off
Published:
10/21/2014

U.S. Rep. John Delaney (D-Md.) got an overview of the NCI at Frederick, heard about the latest advances in the genetics of breast cancer, and toured the Small Animal Imaging Facility during an Oct. 21 visit to the NCI Campus at Frederick.

Delaney was especially interested in the breast cancer presentation by Shyam Sharan, Ph.D., Deputy Program Director, Mouse Cancer Genetics Program, National Cancer Institute (NCI).

Sharan’s laboratory uses humanized mouse models to study human BRCA1 and BRCA2 genes, whose mutations lead to breast cancer. A deeper understanding of how these genes function could aid in the design of improved methods of prevention, diagnosis, and treatment of breast cancers. Humanized mouse models provide an effective system for generating specific mutations that have been identified in human breast cancer patients. These mutations can then be studied to determine how they result in tumorigenesis.

Image: Pictured, from left: Delaney; Dave Heimbrook, Ph.D., Laboratory Director, Frederick National Laboratory for Cancer Research, and President, Leidos Biomedical Research, Inc.; M.K. Holohan, NCI Legislative Office; Dr. Shyam Sharan, Deputy Director, Mouse Genetics Program; Craig Reynolds, Ph.D., Director of Scientific Operations, NCI at Frederick, and Associate Director, National Cancer Institute; Steve Davis, Chief, Management Operations Support Branch, NCI at Frederick; and Blair Feldman, NCI Legislative Office.​

Tagged: